Dr. Susan Slovin on 177Lu-PSMA-617 and the rise of radiopharmaceuticals in mCRPC

Antibody-drug conjugates, including those targeting PSMA, are among the next wave of treatment advances in mCRPC.

The PSMA-PET imaging product is now approved for the selection of patients with metastatic prostate cancer for whom 177Lu-PSMA-617 is indicated.

Once patients had a PSA level of 0.25 ng/mL or higher, the risk of mortality increased by approximately 50%.

The phase 1 PROPELLER trial assessed the safety and efficacy of 64Cu-SAR-bisPSMA, and compared the imaging agent with 68Ga-PSMA-11 PET.

The data come from a sub-analysis of the pivotal phase 3 CONDOR trial of the PSMA-targeted radiopharmaceutical piflufolastat F 18 in men with suspected recurrence of prostate cancer.

“I clearly think that this agent improves the identification of clear cell kidney cancer compared with any metric on any cross-sectional imaging study to date," says Brian M. Shuch, MD.